242 related articles for article (PubMed ID: 25473287)
1. Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation.
Zhang X; Chen G; Zhang T; Ma Z; Wu B
Int J Nanomedicine; 2014; 9():5503-14. PubMed ID: 25473287
[TBL] [Abstract][Full Text] [Related]
2. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
Borkar N; Xia D; Holm R; Gan Y; Müllertz A; Yang M; Mu H
Eur J Pharm Sci; 2014 Jan; 51():204-10. PubMed ID: 24134899
[TBL] [Abstract][Full Text] [Related]
3. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
Jain S; Valvi PU; Swarnakar NK; Thanki K
Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
[TBL] [Abstract][Full Text] [Related]
4. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
[TBL] [Abstract][Full Text] [Related]
5. Significantly enhanced bioavailability of niclosamide through submicron lipid emulsions with or without PEG-lipid: a comparative study.
Zhang X; Zhang Y; Zhang T; Zhang J; Wu B
J Microencapsul; 2015; 32(5):496-502. PubMed ID: 26079596
[TBL] [Abstract][Full Text] [Related]
6. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles.
Yuan H; Chen CY; Chai GH; Du YZ; Hu FQ
Mol Pharm; 2013 May; 10(5):1865-73. PubMed ID: 23495754
[TBL] [Abstract][Full Text] [Related]
7. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide.
Zhang T; Chen J; Zhang Y; Shen Q; Pan W
Eur J Pharm Sci; 2011 Jun; 43(3):174-9. PubMed ID: 21530654
[TBL] [Abstract][Full Text] [Related]
8. [Polyelectrolyte layer-by-layer assembled lipid nanoparticles for improving oral absorption of doxorubicin].
Shen AJ; Xia DN; Gan Y; Li J
Yao Xue Xue Bao; 2016 Jul; 51(7):1136-43. PubMed ID: 29897223
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
Fei Y; Kostewicz ES; Sheu MT; Dressman JB
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
[TBL] [Abstract][Full Text] [Related]
10. Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
Berthelsen R; Holm R; Jacobsen J; Kristensen J; Abrahamsson B; Müllertz A
Mol Pharm; 2015 Apr; 12(4):1062-71. PubMed ID: 25679417
[TBL] [Abstract][Full Text] [Related]
11. Fabrication of fenofibrate nanocrystals by probe sonication method for enhancement of dissolution rate and oral bioavailability.
Ige PP; Baria RK; Gattani SG
Colloids Surf B Biointerfaces; 2013 Aug; 108():366-73. PubMed ID: 23602990
[TBL] [Abstract][Full Text] [Related]
12. Magnesium lithospermate B loaded PEGylated solid lipid nanoparticles for improved oral bioavailability.
Kang X; Chen H; Li S; Jie L; Hu J; Wang X; Qi J; Ying X; Du Y
Colloids Surf B Biointerfaces; 2018 Jan; 161():597-605. PubMed ID: 29156336
[TBL] [Abstract][Full Text] [Related]
13. Chitosan based polymer-lipid hybrid nanoparticles for oral delivery of enoxaparin.
Dong W; Wang X; Liu C; Zhang X; Zhang X; Chen X; Kou Y; Mao S
Int J Pharm; 2018 Aug; 547(1-2):499-505. PubMed ID: 29859924
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the oral bioavailability of silymarin-loaded lipid nanoparticles with their artificial lipolysate counterparts: implications on the contribution of integral structure.
Shangguan M; Qi J; Lu Y; Wu W
Int J Pharm; 2015 Jul; 489(1-2):195-202. PubMed ID: 25956049
[TBL] [Abstract][Full Text] [Related]
15. Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material.
Li W; Zhang T; Ye Y; Zhang X; Wu B
Int J Pharm; 2015 Nov; 495(2):948-55. PubMed ID: 26453780
[TBL] [Abstract][Full Text] [Related]
16. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Ranpise NS; Korabu SS; Ghodake VN
Colloids Surf B Biointerfaces; 2014 Apr; 116():81-7. PubMed ID: 24445002
[TBL] [Abstract][Full Text] [Related]
17. In vitro lipolysis tests on lipid nanoparticles: comparison between lipase/co-lipase and pancreatic extract.
Jannin V; Dellera E; Chevrier S; Chavant Y; Voutsinas C; Bonferoni C; Demarne F
Drug Dev Ind Pharm; 2015; 41(10):1582-8. PubMed ID: 25342478
[TBL] [Abstract][Full Text] [Related]
18. A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.
Jia Z; Lin P; Xiang Y; Wang X; Wang J; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2011 Sep; 79(1):126-34. PubMed ID: 21658449
[TBL] [Abstract][Full Text] [Related]
19. Aminoclay-lipid hybrid composite as a novel drug carrier of fenofibrate for the enhancement of drug release and oral absorption.
Yang L; Shao Y; Han HK
Int J Nanomedicine; 2016; 11():1067-76. PubMed ID: 27042061
[TBL] [Abstract][Full Text] [Related]
20. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
Dahan A; Hoffman A
J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
